Testing VRT106 with radiation for adults with diffuse midline glioma
Original title: A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the drug is still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a drug called VRT106 given with radiation.
Who this trial is for. This trial is for adults with diffuse midline glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary or DIPG. It tests a drug called VRT106 given along with radiation.
Where it stands. This trial has not reported results. It is looking at early signs of how well VRT106 works. It is also checking how safe the drug is. It is checking how well people handle it. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: Someone who fits this group could ask their care team about this trial. The team can say if it makes sense for them.
What it doesn't mean: This does not mean the drug works. A trial is a test, not a proven treatment. Being in one is not a promise of help. It is not a cure.
Source: ClinicalTrials.gov, October 30, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.